Hugh Taylor

Has grant

Chair Obstetrics and Gynecology

Yale University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Inhibition of miRNA (miR-451a) as a possible treatment option for systemic effects of endometriosis

Open Date: 2024-01-01

Close Date:

Grant: Close

Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss

Open Date: 2021-04-15

Close Date: 2026-10-31

Grant: Close

Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4

Open Date: 2019-09-26

Close Date: 2026-08-31

Grant: Close

Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4

Open Date: 2019-09-26

Close Date: 2025-06-30

Grant: Close

Multi-center prospective study assessing a panel of microRNAs as a non-invasive test for endometriosis

Open Date: 2019-05-01

Close Date: 2021-04-30

Articles (23)

Year:

2026

Year:

2026

Background: Biological sex has been shown to influence aging outcomes, contributing to distinct trajectories in disease susceptibility and lifespan. DNA methylation patterns provide a quantitative measure of biological aging. This study investigated whether aged male and female mice display distinct liver DNA methylation patterns and differences in epigenetic aging. Methods: Liver samples were collected from 17 aged c57BL/6 mice (6 males, 11 females). Genomic DNA was extracted and bisulfite-converted prior to targeted enrichment of 2,045 murine age-associated CpG loci. Biological age (DNAge®) was estimated using a previously developed DNA methylation-based predictor generated through elastic net regression. The difference (ΔDNAge®) between DNAge® and chronological age was computed. Sex-specific differences were assessed by comparing site-specific methylation ratios, ΔDNAge® values, and through principal component analysis (PCA) and multiple linear regression. Results: Twelve CpG sites across six genes ( Fam84b, Zswim6, Hsf4, Mn1, Qprt, and Rapgefl1) showed significant sex-associated differences in methylation. Fam84b demonstrated the largest and most consistent sex-associated effect, with all three associated CpG sites showing higher methylation in males (regression coefficients: -0.204, -0.281, -0.294). Zswim6 exhibited consistent lower methylation ratios in females, while the other genes showed higher methylation in females. There were no sex differences in biological age or ΔDNAge® (p = 0.596). Conclusions: Although the epigenetic clock did not reveal differences between sexes in aging, aged mice did exhibit sex-specific liver methylation patterns different from those reported in younger mice, suggesting that sex-dependent epigenetic changes may emerge later in life and may reflect sexual dimorphism in liver function with age.

Year:

2026

Year:

2025

Year:

2025

Asherman Syndrome (AS) is caused by injury to the endometrium leading to uterine scarring, decreased menstruation and infertility; it typically occurs after surgical curettage of the uterus. AS is treated surgically albeit with limited success. Administration of bone marrow‐derived mesenchymal stem cells (MSCs) has recently been demonstrated to restore uterine function in AS; however, there is no data available on the role of the estrous cycle phase on outcomes. Here, we describe endometrial injury during estrus or diestrus, its differential effect on fertility, and its response after bone marrow MSC treatment to reverse the infertility in a murine model. Endometrial injury in the estrus phase did not affect fertility outcomes whereas injury in the diestrus phase resulted in infertility. Bone marrow (BM)‐derived MSC treatment without injury in the estrus or diestrus phase did not affect the pregnancy outcomes. BM MSC treatment following endometrial injury in the diestrus phase restored fertility. Immunofluorescence analysis revealed that vimentin or cytokeratin‐positive BM‐derived cells in the uterus were extremely rare. BM MSC treatment after injury increased CD45 + cells, indicating a role for immunomodulation in endometrial repair. Finally, qRT‐PCR showed that Ccl3 , Il‐1β and Mmp3 gene expression was significantly higher in the endometrium of the injury + BM MSC group than in other groups. In summary, injury to the endometrium during the diestrus phase results in infertility that can be restored by the treatment of BM MSCs. The therapeutic effect of BM MSCs on the endometrium appears to be mediated primarily by immunomodulation rather than BM MSC engraftment.

Year:

2025

Adenomyosis is a chronic, estrogen-driven disorder characterized by the presence of endometrial glands and stroma within the myometrium. Despite its significant impact on reproductive health and quality of life, the pathogenesis of the disease remains unclear. Both the glandular and stromal compartments of eutopic endometrium from women with adenomyosis show alterations compared to healthy subjects. However, the molecular mechanisms driving crosstalk between stromal cells and epithelial glands, along with paracrine signaling underlying lesion development and progression, are still poorly understood. Exosomes, small cell-derived carriers and microRNAs, namely non-coding RNA molecules, are crucial to intercellular communication within the endometrium and may elucidate interactions between the two compartments that contribute to adenomyotic lesion formation. To our knowledge, this is the first foundational study to comprehensively isolate and characterize stroma-derived exosomes from women with adenomyosis. Exosome isolation by means of differential ultracentrifugation was validated in 22 samples, including 11 healthy subjects and 11 women with adenomyosis, using nanoparticle tracking analysis, transmission electron microscopy, and flow cytometry. Profiling of microRNA in secreted exosomes revealed 10 microRNAs with significantly altered expression in adenomyosis subjects during the menstrual phase compared to controls. Thorough investigations into menstruation-specific molecular mechanisms, as well as predicted target genes and enriched pathways of exosomal microRNAs, offer promising insights into the pathogenesis of adenomyosis, shedding light on the potential mechanisms underlying stromal cell signaling and adenomyotic lesion establishment. This work does, however, have certain drawbacks, including modest sample size and limited representation due to a lack of readily available endometrial biopsies in the menstrual phase. Having done the groundwork in this study, future research should seek to validate these findings in larger cohorts and apply functional assays. Indeed, our findings can serve as a resource to elucidate the role of menstruation-specific stroma-derived microRNA-mediated signaling and its potential impact on adenomyosis development.

Year:

2025

Background Evidence suggests that endometrioma cystectomy can significantly reduce ovarian reserve. Ethanol sclerotherapy is a promising, minimally invasive alternative. This overview aims to critically evaluate systematic reviews that addressed the safety and efficacy of ethanol sclerotherapy in women with endometrioma and compared it to endometriotic cystectomy. Methods A systematic search was conducted on PubMed, Medline, Epistemonikos, the Cochrane Library, and PROSPERO using the search terms “endometriosis OR endometrioma AND sclerotherapy.” Key outcomes assessed included adverse events, technical efficacy, pain relief, endometrioma recurrence, impact on ovarian reserve, ART success, and pregnancy outcomes. Two independent reviewers screened, reviewed, and selected relevant publications. They also evaluated the quality of the included systematic reviews using the modified version of the Assessing the Methodological Quality of Systematic Reviews (AMSTAR2) tool. Furthermore, they assessed the strength of evidence for the primary outcome measures according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The study protocol was registered in advance at PROSPERO under registration number CRD42024595209 on 10 October 2024. Results Nine systematic reviews were eligible, analyzing between 386 and 1,642 procedures. The reviews reported high technical efficacy (95.0%-98.3%) and low adverse events (11.0%-12.0% minor, 1.0%-1.7% major). Outcomes for pain relief, ovarian reserve, and pregnancy rates were generally favorable. Pregnancy rates for ethanol sclerotherapy and endometriotic cystectomy appeared comparable; however, sclerotherapy resulted in larger number of eggs retrieved and no loss of ovarian reserve. Overall, the strength of evidence for sclerotherapy was low to very low. though larger sample sizes supported findings on technical efficacy and adverse events. Conclusions Ethanol sclerotherapy is a viable alternative to endometriotic cystectomy for treating endometrioma in reproductive-age women. It has the advantage of being safe and effective for pain relief and potentially superior to cystectomy in preserving ovarian reserve. Future studies should evaluate sclerotherapy compared to cystectomy and expectant management in randomized controlled trials. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024595209.

Year:

2025

Previous epidemiological studies have suggested that green tea catechins, including Epigallocatechin‐3‐gallate (EGCG), the most abundant polyphenol in green tea, may be associated with reduced serum folate levels. This is of particular interest as women of childbearing age may be consuming EGCG from tea, dietary supplements, or involved in active clinical trials studying EGCG or green tea extract. EGCG was reported to shrink uterine fibroids in preclinical and clinical studies. This observation led to the development of a multicenter NICHD‐funded clinical trial to evaluate the safety of EGCG for treating women with fibroids and unexplained infertility (NCT04177693). To answer the question of whether green tea extract standardized to EGCG led to a reduction in folate, 39 women aged ≥ 18 to ≤ 40 years, with/without uterine fibroids, were evaluated. These women were randomized to receive either EGCG, EGCG + clomiphene, or EGCG + letrozole for 30 days. A daily dose of 720 mg of highly characterized green tea extract containing EGCG was used. Participants were genotyped for polymorphisms at positions 677 and 1298 in MTHFR and for the −19 bp deletion polymorphism of DHFR. During the intervention with EGCG, folate levels remained in the normal range in all subjects. Our data suggest that in reproductive‐age women, a 30‐day course of EGCG 720 mg daily taken alone or in combination with clomiphene citrate or letrozole (for 5 days) is well‐tolerated and is not associated with folate deficiency even in the presence of MTHFR and/or DHFR polymorphisms known to negatively impact folate synthesis. Trial Registration: Clinical trial: NCT 01311869

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (12)

Christian M Becker

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Marie-Madeleine Dolmans

Université catholique de Louvain

BELGIUM
View details

Andrew W Horne

University of Edinburgh

UNITED KINGDOM
View details

Megan M. Wenner

University of Delaware

UNITED STATES
View details

Xavier Santamaria

Investigador biomédico, especialidad ginecología

Vall d'Hebron Institut de Recerca

SPAIN
View details

Ido Izhaki

Dean, School of Graduate Studies

-

ISRAEL
View details

Rebecca Slutsky

-

UNITED STATES
View details

Kieran O'Donnell

Associate Professor

Yale University

UNITED STATES
View details

Philippe Pinton

Senior Vice President, Global Head

Ferring Pharmaceuticals (Denmark)

DENMARK
View details

David Edwards

Professor

University of Delaware

UNITED STATES
View details

Felice PETRAGLIA

Professore Ordinario

Università degli Studi di Siena

ITALY
View details

Oksana Goroshchuk

Karolinska University Hospital

SWEDEN
View details